ISSN: 2167-0501
Lukas Feldmann*
Cardiovascular Diseases (CVDs) remain the leading cause of death globally, necessitating the urgent need for efficient strategies in their early detection and prognosis. Over the last two decades, the field of cardiovascular diagnostics has increasingly shifted toward identifying and validating biochemical biomarkers that provide insight into disease progression, therapeutic response, and potential outcomes. Biomarkers are objective, quantifiable indicators of physiological and pathological processes or pharmacologic responses to a therapeutic intervention. In the context of CVDs, such markers not only aid in confirming diagnoses but also help stratify patients based on risk, enabling personalized treatment approaches.
Published Date: 2025-03-04; Received Date: 2025-02-03